scholarly journals Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review

2017 ◽  
Vol 58 (1) ◽  
pp. 22-39 ◽  
Author(s):  
Alaa Qassim ◽  
Ben W. Mol ◽  
Rosalie M. Grivell ◽  
Luke E. Grzeskowiak
Keyword(s):  
Systematic Review ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Safety And Efficacy ◽  
In Pregnancy

scholarly journals Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose

2012 ◽  
Vol 40 (5) ◽  
Author(s):  
Patricia Christoph ◽  
Christine Schuller ◽  
Hanna Studer ◽  
Olivier Irion ◽  
Begoña Martinez De Tejada ◽  
...  
Keyword(s):  
Intravenous Iron ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
High Dose ◽  
Iron Treatment ◽  
In Pregnancy

scholarly journals Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease

2019 ◽  
Vol 6 ◽  
pp. 2333794X1987098
Author(s):  
Ramy Sabe ◽  
Anant Vatsayan ◽  
Amr Mahran ◽  
Ali S. Khalili ◽  
Sanjay Ahuja ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Bowel Disease ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Safety And Efficacy ◽  
Normal Ranges ◽  
Inflammatory Bowel

Background. Anemia is common in inflammatory bowel disease (IBD). Oral iron is widely used but efficacy can be reduced by poor compliance and insufficient absorption. Intravenous iron is safe and effective in adults but is not well studied in children. Purpose. To assess safety and efficacy of intravenous iron sucrose (IVIS) in children with IBD. Methods. We reviewed medical records of IBD patients <22 years of age who received IVIS at our institution between 2009 and 2014. Anemia was defined as hemoglobin (Hgb) level below normal for age and gender and iron-deficiency anemia as serum iron studies and red cell mean corpuscular volume below normal ranges. Each IVIS infusion was evaluated for safety. Efficacy was defined as ≥2 g/dL increase in Hgb ≤12 weeks from IVIS initiation. Results. We identified 88 patients (Crohn’s disease, n = 52; ulcerative colitis, n = 33; IBD-unclassified, n = 3) who underwent 329 IVIS infusions over 121 courses. No patient developed anaphylaxis. Six patients developed minor adverse reactions. Of the 121 IVIS courses, 80 were included in the efficacy evaluation. There was a significant rise in Hgb (mean 9.1 ±1.4 to 11.9 ± 1.8 g/dL; P < .0001, paired t test). Overall, 58.7% (47/80 courses) resulted in goal Hgb increase. Conclusions. IVIS is safe and effective in treating iron-deficiency anemia in pediatric IBD. There were only minor adverse events, and the observed rise in Hgb was clinically significant, with the majority achieving goal Hgb.

scholarly journals Randomized clinical trial to evaluate ferric carboxymaltose and iron sucrose for treatment of postpartum anaemia in a tertiary hospital

2018 ◽  
Vol 7 (11) ◽  
pp. 4551
Author(s):  
Sheela H. S. ◽  
Ashwini Neelakanthi ◽  
Nikitha C. P.
Keyword(s):  
Intravenous Iron ◽  
Tertiary Hospital ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Treatment Groups ◽  
Baseline Haemoglobin ◽  
Target Haemoglobin ◽  
Calculated Dose ◽  
Iron Delivery

Background: Ferric carboxymaltose and iron sucrose are two iron carbohydrate complexes optimized for iron delivery and extensively used in postpartum anaemia. This study compares the efficacy and safety of ferric carboxymaltose with that of iron sucrose in patients with postpartum anaemia.Methods: One hundred women diagnosed with postpartum anaemia were randomized prospectively in a 1:1 ratio to receive either ferric carboxymaltose or iron sucrose. Fifty patients received intravenous iron carboxymaltose depending on the iron deficit at rate of 1000 mg/week and fifty patients received intravenous iron sucrose at a rate of 200 mg/day on alternate days till the calculated dose is given.Results: Fifty patients were enrolled in each treatment group. Both groups showed increases in mean haemoglobin from baseline at 2 weeks and 6 weeks. The increase in haemoglobin was significantly higher in ferric carboxymaltose group compared to iron sucrose at both week 2 (2.64±0.91 versus 2.17±0.76; p=0.010) and week 6 timepoints (4.65±1.17 versus 3.96±1.06; p=0.005). The proportion of patients achieving target haemoglobin of 12 gm/dl was significantly higher in ferric carboxymaltose group compared to iron sucrose at week 6 (77.3% versus 50.0%; p=0.013). The incidence of adverse events was similar across treatment groups and no specific safety concerns were observed.Conclusions: Both ferric carboxymaltose and iron sucrose caused increase in baseline haemoglobin. Ferric carboxymaltose had significantly higher increases in haemoglobin compared to iron sucrose at both follow up timepoints (week 2 and week 6). It was more likely to achieve target haemoglobin with ferric carboxymaltose within 6 weeks compared to iron sucrose. Ferric carboxymaltose may be considered in women with postpartum anaemia for faster rise in haemoglobin while requiring fewer injections compared to iron sucrose.

Sign in / Sign up

Export Citation Format

Share Document